The objective of this trial is to evaluate the impact of elimination of albumin bound substances during albumin dialysis (MARS®) on mortality and the clinical time course in patients with a recent severe clinical deterioration of chronic liver disease caused by a precipitating (trigger) event within 4 weeks manifested by jaundice, encephalopathy and/or renal failure.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Signed written informed consent by patient or next of kin
* Age greater than 18 years
* Patients with a recent clinical severe decompensation of a presumed cirrhosis (based on clinical evaluation or radiological imaging) related to a precipitating (trigger) event (e.g. infection, bleeding, alcohol abuse)
* Intrahepatic cholestasis (bilirubin greater than 5 mg/dl or greater than 85 µmol/l, respectively) without evidence of extrahepatic origin
* and at least one of the following three:
* Hepatorenal syndrome (impaired renal function with creatinine greater than 1.5 mg/dl or greater than 133µmol/l without evidence of reduced vascular volume \[e.g. central venous pressure {CVP} greater than 8 cm H2O\] and no evidence of pre-existing renal failure)
* Hepatic Encephalopathy greater than or equal to II°
* Progressive Hyperbilirubinaemia: defined as a more than 50% increase of bilirubin before enrolment, whether in referral or currently in hospital up to a level of greater than 20 mg/dl (or greater than 340 µmol/l)
Exclusion Criteria:
* Progressive jaundice and deterioration as a natural course of a chronic liver disease without precipitating (trigger) event
* Severe thrombocytopenia (platelet count less than or equal to 50 Glutamic Pyruvic Transaminase \[GPT\]/l)
* Severe coagulopathy (International Normalised Ratio \[INR\] greater than 2.3)
* Need for renal replacement therapy within three days prior to enrolment
* Severe infection without antibiotic treatm…
What they're measuring
1
Show improvement of transplant free survival under MARS in comparison to Standard Medical Treatment.